KR101498848B1 - 신경섬유종증의 치료를 위한 피리미딜아미노벤즈아미드 유도체 - Google Patents

신경섬유종증의 치료를 위한 피리미딜아미노벤즈아미드 유도체 Download PDF

Info

Publication number
KR101498848B1
KR101498848B1 KR1020137034055A KR20137034055A KR101498848B1 KR 101498848 B1 KR101498848 B1 KR 101498848B1 KR 1020137034055 A KR1020137034055 A KR 1020137034055A KR 20137034055 A KR20137034055 A KR 20137034055A KR 101498848 B1 KR101498848 B1 KR 101498848B1
Authority
KR
South Korea
Prior art keywords
treatment
lower alkyl
acid
phenyl
neurofibromatosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020137034055A
Other languages
English (en)
Korean (ko)
Other versions
KR20140022431A (ko
Inventor
폴 더블유. 맨리
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20140022431A publication Critical patent/KR20140022431A/ko
Application granted granted Critical
Publication of KR101498848B1 publication Critical patent/KR101498848B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020137034055A 2005-12-06 2006-12-05 신경섬유종증의 치료를 위한 피리미딜아미노벤즈아미드 유도체 Expired - Fee Related KR101498848B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74278105P 2005-12-06 2005-12-06
US60/742,781 2005-12-06
PCT/EP2006/069335 WO2007065898A1 (en) 2005-12-06 2006-12-05 Pyrimidylaminobenzamide derivatives for the treatment of neurofibromatosis

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020087013614A Division KR101413387B1 (ko) 2005-12-06 2006-12-05 신경섬유종증의 치료를 위한 피리미딜아미노벤즈아미드유도체

Publications (2)

Publication Number Publication Date
KR20140022431A KR20140022431A (ko) 2014-02-24
KR101498848B1 true KR101498848B1 (ko) 2015-03-05

Family

ID=37831665

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020137034055A Expired - Fee Related KR101498848B1 (ko) 2005-12-06 2006-12-05 신경섬유종증의 치료를 위한 피리미딜아미노벤즈아미드 유도체
KR1020087013614A Expired - Fee Related KR101413387B1 (ko) 2005-12-06 2006-12-05 신경섬유종증의 치료를 위한 피리미딜아미노벤즈아미드유도체

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020087013614A Expired - Fee Related KR101413387B1 (ko) 2005-12-06 2006-12-05 신경섬유종증의 치료를 위한 피리미딜아미노벤즈아미드유도체

Country Status (13)

Country Link
US (4) US20080318988A1 (enExample)
EP (2) EP1959957B1 (enExample)
JP (4) JP2009518358A (enExample)
KR (2) KR101498848B1 (enExample)
CN (1) CN101321532B (enExample)
AU (1) AU2006323992B2 (enExample)
BR (1) BRPI0619416A2 (enExample)
CA (1) CA2629132C (enExample)
ES (2) ES2549327T3 (enExample)
PL (1) PL1959957T3 (enExample)
PT (1) PT1959957E (enExample)
RU (1) RU2450814C2 (enExample)
WO (1) WO2007065898A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2450814C2 (ru) * 2005-12-06 2012-05-20 Новартис Аг Производные пиримидиламинобензамида, предназначенные для лечения нейрофиброматоза
US8242271B2 (en) 2007-06-04 2012-08-14 Avila Therapeutics, Inc. Heterocyclic compounds and uses thereof
WO2009158447A2 (en) * 2008-06-27 2009-12-30 Indiana University Research And Technology Corporation Materials and methods for suppressing and/or treating neurofibroma and related tumors
KR20110053354A (ko) * 2008-08-13 2011-05-20 노파르티스 아게 폐동맥 고혈압의 치료
EP2186514B1 (en) 2008-11-14 2016-06-29 Kinki University Treatment of Malignant Peripheral Nerve Sheath Tumors
BR112012009094A8 (pt) * 2009-10-23 2017-10-10 Novartis Ag método de tratamento de transtornos proliferativos e outras condições patológicas mediadas por bcr-abl, c-kit, ddr1,ddr2 ou atividade pdgf-r quinase
JP7230817B2 (ja) 2017-10-03 2023-03-01 凸版印刷株式会社 超音波シール用アンビル及び超音波シール装置
TWI787523B (zh) 2018-06-15 2022-12-21 漢達生技醫藥股份有限公司 達沙替尼十二烷基硫酸鹽之結晶
WO2026035611A1 (en) * 2024-08-05 2026-02-12 Amo Pharma Ltd Methods of treating neurofibromatosis using farnesyl dibenzodiazepinones

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004005281A1 (en) * 2002-07-05 2004-01-15 Novartis Ag Inhibitors of tyrosine kinases
WO2005049032A1 (en) * 2003-11-18 2005-06-02 Novartis Ag Inhibitors of the mutant form of kit

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0325031D0 (en) 2003-10-27 2003-12-03 Novartis Ag Organic compounds
PT1843771E (pt) * 2005-01-28 2011-12-02 Novartis Ag Uso de pirimidilaminobenzamidas para o tratamento de doenças que respondem à modulação da atividade da cinase tie-2
RU2450814C2 (ru) * 2005-12-06 2012-05-20 Новартис Аг Производные пиримидиламинобензамида, предназначенные для лечения нейрофиброматоза

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004005281A1 (en) * 2002-07-05 2004-01-15 Novartis Ag Inhibitors of tyrosine kinases
WO2005049032A1 (en) * 2003-11-18 2005-06-02 Novartis Ag Inhibitors of the mutant form of kit

Also Published As

Publication number Publication date
BRPI0619416A2 (pt) 2011-10-04
CN101321532A (zh) 2008-12-10
US20140073660A1 (en) 2014-03-13
JP2017193553A (ja) 2017-10-26
KR20080077973A (ko) 2008-08-26
PT1959957E (pt) 2012-10-29
PL1959957T3 (pl) 2012-12-31
KR101413387B1 (ko) 2014-06-27
RU2450814C2 (ru) 2012-05-20
ES2391199T3 (es) 2012-11-22
EP2177222B1 (en) 2015-07-15
CA2629132C (en) 2014-05-27
EP1959957B1 (en) 2012-07-18
US20080318988A1 (en) 2008-12-25
EP1959957A1 (en) 2008-08-27
AU2006323992A1 (en) 2007-06-14
KR20140022431A (ko) 2014-02-24
CA2629132A1 (en) 2007-06-14
JP2015091818A (ja) 2015-05-14
EP2177222A1 (en) 2010-04-21
RU2008127264A (ru) 2010-01-20
WO2007065898A1 (en) 2007-06-14
ES2549327T3 (es) 2015-10-27
US20100234408A1 (en) 2010-09-16
JP2009518358A (ja) 2009-05-07
AU2006323992B2 (en) 2010-07-08
CN101321532B (zh) 2011-06-29
US8604045B2 (en) 2013-12-10
US20130123290A1 (en) 2013-05-16
JP2013107893A (ja) 2013-06-06

Similar Documents

Publication Publication Date Title
US8604045B2 (en) Pyrimidylaminobenzamide derivatives for treatment of neurofibromatosis
US8673930B2 (en) Pyrimidylaminobenzamide derivatives for systemic mastocytosis
JP2007513967A (ja) 変異レセプターチロシンキナーゼが駆動する細胞増殖性疾患の処置において使用するための組成物
JP5154408B2 (ja) 好酸球増加症候群のためのピリミジルアミノベンズアミド誘導体
JP5751568B2 (ja) 悪性末梢神経鞘腫瘍の処置

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

Fee payment year number: 1

St.27 status event code: A-2-2-U10-U12-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20180201

Year of fee payment: 4

PR1001 Payment of annual fee

Fee payment year number: 4

St.27 status event code: A-4-4-U10-U11-oth-PR1001

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

Not in force date: 20190227

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

St.27 status event code: A-4-4-U10-U13-oth-PC1903

PC1903 Unpaid annual fee

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20190227

St.27 status event code: N-4-6-H10-H13-oth-PC1903

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000